Psilocybin Assisted Therapy Industry - Regional Synopsis
Regionally, the global psilocybin assisted therapy market is studied into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region. North America industry is anticipated to hold largest revenue share by 2037, led by higher growth rate in the intranasal segment as companies launch novel psychedelic sprays and proven efficacy increases its popularity.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
The psilocybin assisted therapy industry size is anticipated to witness more than 4.3% CAGR during the forecast period i.e., between 2025-2037.
Rising prevalence of depression and mental disorders and high use in the treatment of anxiety will impel the market growth.
North America industry is anticipated to hold largest revenue share by 2037, led by higher growth rate in the intranasal segment as companies launch novel psychedelic sprays and proven efficacy increases its popularity.
The major players in the market are Cybin Irl Limited, Mind Medicine Inc., COMPASS Pathways plc, Atai Life Sciences N.V., Fieldtrip, LLC., DemeRx, Hikma Pharmaceuticals PLC, Jazz Pharmaceuticals Inc, Pfizer Inc., Others.
